FAQ

• Patients with ISM can experience a variety of symptoms across multiple organ systems⁵
• Common symptoms of ISM include skin lesions, itching, anaphylaxis or severe allergic reactions, diarrhea, and nausea⁵
• These are not all of the possible symptoms patients with ISM may experience⁵

• Avapritinib is a tyrosine kinase inhibitor designed for the potent and selective inhibition of KIT D816V^1,9
• Patients do not need to be KIT D816V positive to receive treatment with AYVAKIT¹

Avapritinib is a tyrosine kinase inhibitor approved as an oral therapy for adults with indolent systemic mastocytosis.¹ Avapritinib is designed to target and inhibit a specific mutation called KIT D816V that drives abnormal growth and division of mast cells.^1,18 Conventional, classical chemotherapy works by destroying rapidly growing and dividing cells.¹⁸

PIONEER was a phase 2, multipart, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of AYVAKIT 25 mg (N=141) vs placebo (N=71)—both with concomitant best supportive care over 24 weeks in adult patients with indolent systemic mastocytosis.^1,9

The most common adverse reactions (≥10%) in patients with ISM treated with AYVAKIT were eye edema, dizziness, peripheral edema, and flushing.¹
Refer to the full Prescribing Information for AYVAKIT for further overall adverse event information.¹

• Serious ICH may occur with AYVAKIT treatment; fatal events occurred in <1% of patients¹
• No events of ICH occurred in the 246 patients with ISM who received any dose of AYVAKIT in the PIONEER study¹
• Monitor your patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia¹
• Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status¹
• Advise patients to seek immediate medical attention for signs and symptoms of ICH¹
• Permanently discontinue AYVAKIT if ICH of any grade occurs¹

Please see the Important Safety Information and the full Prescribing Information for AYVAKIT for additional guidance.

• Based on findings from animal studies, AYVAKIT may impair female and male fertility. These findings were not reversible within a 2-month recovery period¹
• Advise females of reproductive potential that AYVAKIT may impair fertility at 200 mg or 300 mg¹
• Advise males of reproductive potential that AYVAKIT may decrease sperm production at 200 mg or 300 mg¹

To learn about taking AYVAKIT while pregnant or breastfeeding, please see the full Prescribing Information.

• The recommended dosage of AYVAKIT is 25 mg orally, once daily in patients with indolent systemic mastocytosis¹
• Administer AYVAKIT orally on an empty stomach, at least 1 hour before or at least 2 hours after a meal¹
• A modified starting dosage of AYVAKIT is recommended for patients with severe hepatic impairment (Child-Pugh Class C): 25 mg orally every other day¹
• Avoid concomitant use of AYVAKIT with strong or moderate CYP3A inhibitors or inducers¹

Learn about the dosing and administration of AYVAKIT and please see the full Prescribing Information.

Indolent systemic mastocytosis is a chronic disease and, as such, AYVAKIT is intended as a chronic treatment.^1,7 The Prescribing Information for AYVAKIT does not define a duration of use in indolent systemic mastocytosis.¹

Approval processes and AYVAKIT prior authorization requirements vary by payer. YourBlueprint^® can help navigate the prior authorization process for your patient.

YourBlueprint^® provides dedicated, personalized support to help your eligible patients from day 1 when you enroll them at the time of prescription. Blueprint Medicines offers a series of programs to support patient access including: co-pay support, prior authorization support, coverage interruption, QuickStart, and more.

The SM Provider Peer Directory is an online resource that lists the contact information of volunteer healthcare providers who have experience managing patients living with systemic mastocytosis and/or treating patients taking AYVAKIT and are willing to independently connect with peers who have questions about their medical experience.